Contrast-enhanced mammography for surveillance in women with a personal history of breast cancer.
Breast cancer
CEM
Contrast
Mammography
Surveillance
Journal
Breast cancer research and treatment
ISSN: 1573-7217
Titre abrégé: Breast Cancer Res Treat
Pays: Netherlands
ID NLM: 8111104
Informations de publication
Date de publication:
04 Jul 2024
04 Jul 2024
Historique:
received:
28
04
2024
accepted:
27
06
2024
medline:
4
7
2024
pubmed:
4
7
2024
entrez:
4
7
2024
Statut:
aheadofprint
Résumé
Women with a personal history of breast cancer have an increased risk of subsequent breast malignancy and may benefit from more sensitive surveillance than conventional mammography (MG). We previously reported outcomes for first surveillance episode using contrast-enhanced mammography (CEM), demonstrating higher sensitivity and comparable specificity to MG. We now report CEM performance for subsequent surveillance. A retrospective study of 1,190 women in an Australian hospital setting undergoing annual surveillance following initial surveillance CEM between June 2016 and December 2022. Outcome measures were recall rate, cancer detection rate, contribution of contrast to recalls, false positive rate, interval cancer rate and characteristics of surveillance detected and interval cancers. 2,592 incident surveillance episodes were analysed, of which 93% involved contrast-based imaging. Of 116 (4.5%) recall episodes, 40/116 (34%) recalls were malignant (27 invasive; 13 ductal carcinoma in situ), totalling 15.4 cancers per 1000 surveillance episodes. 55/116 (47%) recalls were contrast-directed including 17/40 (43%) true positive recalls. Tumour features were similar for contrast-directed recalls and other diagnoses. 8/9 (89%) of contrast-directed invasive recalls were Grade 2-3, and 5/9 (56%) were triple negative breast cancers. There were two symptomatic interval cancers (0.8 per 1000 surveillance episodes, program sensitivity 96%). Routine use of CEM in surveillance of women with PHBC led to an increase in the detection of clinically significant malignant lesions, with a low interval cancer rate compared to previous published series. Compared to mammographic surveillance, contrast-enhanced mammography increases the sensitivity of surveillance programs for women with PHBC.
Identifiants
pubmed: 38963525
doi: 10.1007/s10549-024-07419-2
pii: 10.1007/s10549-024-07419-2
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Informations de copyright
© 2024. The Author(s).
Références
Houssami N, Abraham LA, Miglioretti DL et al (2011) Accuracy and outcomes of screening mammography in women with a personal history of early-stage breast cancer. JAMA 305:790–799. https://doi.org/10.1001/jama.2011.188
doi: 10.1001/jama.2011.188
pubmed: 21343578
pmcid: 3799940
Houssami N, Miglioretti DL (2011) Early detection of breast cancer the second time around: mammography in women with a personal history of breast cancer. Med J Aust 194:439–440. https://doi.org/10.5694/j.1326-5377.2011.tb03054.x
doi: 10.5694/j.1326-5377.2011.tb03054.x
pubmed: 21534896
Buist DSM, Abraham LA, Barlow WE et al (2010) Diagnosis of second breast cancer events after initial diagnosis of early stage breast cancer. Breast Cancer Res Tr 124:863–873. https://doi.org/10.1007/s10549-010-1106-6
doi: 10.1007/s10549-010-1106-6
Lam DL, Houssami N, Lee JM (2017) Imaging surveillance after primary breast cancer treatment. Am J Roentgenol 208:676–686. https://doi.org/10.2214/ajr.16.16300
doi: 10.2214/ajr.16.16300
Network NCC NCCN clinical practice guidelines in oncology: breast cancer. Version 4.2023. https://www.nccn.org/professionals/physician_gls/pdf/breast.pdf
Lawson MB, Herschorn SD, Sprague BL et al (2022) Imaging surveillance options for individuals with a personal history of breast cancer: AJR expert panel narrative review. Am J Roentgenol 219:854–868. https://doi.org/10.2214/ajr.22.27635
doi: 10.2214/ajr.22.27635
Harada-Shoji N, Suzuki A, Ishida T et al (2021) Evaluation of adjunctive ultrasonography for breast cancer detection among women aged 40–49 years with varying breast density undergoing screening mammography. Jama Netw Open 4:e2121505. https://doi.org/10.1001/jamanetworkopen.2021.21505
doi: 10.1001/jamanetworkopen.2021.21505
pubmed: 34406400
pmcid: 8374606
Ohuchi N, Suzuki A, Sobue T et al (2016) Sensitivity and specificity of mammography and adjunctive ultrasonography to screen for breast cancer in the Japan strategic anti-cancer randomized trial (J-START): a randomised controlled trial. Lancet 387:341–348. https://doi.org/10.1016/s0140-6736(15)00774-6
doi: 10.1016/s0140-6736(15)00774-6
pubmed: 26547101
Berg WA, Blume JD, Cormack JB et al (2008) Combined screening with ultrasound and mammography vs mammography alone in women at elevated risk of breast cancer. JAMA 299:2151–2163. https://doi.org/10.1001/jama.299.18.2151
doi: 10.1001/jama.299.18.2151
pubmed: 18477782
pmcid: 2718688
Kim GR, Cho N, Kim S-Y et al (2021) Interval cancers after negative supplemental screening breast mri results in women with a personal history of breast cancer. Radiology 300:314–323. https://doi.org/10.1148/radiol.2021203074
doi: 10.1148/radiol.2021203074
pubmed: 34100684
Fonseca MM, Alhassan T, Nisha Y et al (2022) Randomized trial of surveillance with abbreviated MRI in women with a personal history of breast cancer–impact on patient anxiety and cancer detection. BMC Cancer 22:774. https://doi.org/10.1186/s12885-022-09792-x
doi: 10.1186/s12885-022-09792-x
pubmed: 35840916
pmcid: 9287889
Haas CB, Nekhlyudov L, Lee JM et al (2020) Surveillance for second breast cancer events in women with a personal history of breast cancer using breast MRI: a systematic review and meta-analysis. Breast Cancer Res Tr 181:255–268. https://doi.org/10.1007/s10549-020-05637-y
doi: 10.1007/s10549-020-05637-y
Cardoso F, Kyriakides S, Ohno S et al (2019) Early breast cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up †. Ann Oncol 30:1194–1220. https://doi.org/10.1093/annonc/mdz173
doi: 10.1093/annonc/mdz173
pubmed: 31161190
Runowicz CD, Leach CR, Henry NL et al (2016) (2016) American cancer society/American society of clinical oncology breast cancer survivorship care guideline. J Clin Oncol 34(6):611–635. https://doi.org/10.3322/caac.21319
doi: 10.3322/caac.21319
pubmed: 26644543
Neeter LM, Robbe MQ, van Nijnatten TJ, Jochelson MS, Raat HP, Wildberger JE, Smidt ML, Nelemans PJ, Lobbes MB (2023) Comparing the diagnostic performance of contrast-enhanced mammography and breast MRI: a systematic review and meta-analysis. J Cancer 14(174):182. https://doi.org/10.7150/jca.79747
doi: 10.7150/jca.79747
Elder K, Matheson J, Nickson C et al (2023) Contrast enhanced mammography in breast cancer surveillance. Breast Cancer Res Treat 199:221–230. https://doi.org/10.1007/s10549-023-06916-0
doi: 10.1007/s10549-023-06916-0
pubmed: 36966271
pmcid: 10175447
Morris E, Comstock C, Lee C, al et (2013) ACR BI-RADS® Magnetic resonance imaging. In: ACR BI-RADS® atlas, breast imaging reporting and data system. American College of Radiology, Reston, VA
Lee C, Phillips J, Sung J, et al (2022) Contrast-enhanced mammography (CEM). a supplement to ACR BIRADS® mammography 2013. American College of Radiology, Reston, VA
Yoder R, Kimler BF, Staley JM et al (2022) Impact of low versus negative estrogen/progesterone receptor status on clinico-pathologic characteristics and survival outcomes in HER2-negative breast cancer. Npj Breast Cancer 8:80. https://doi.org/10.1038/s41523-022-00448-4
doi: 10.1038/s41523-022-00448-4
pubmed: 35817765
pmcid: 9273627
Allison KH, Hammond MEH, Dowsett M et al (2020) Estrogen and progesterone receptor testing in breast cancer: ASCO/CAP guideline update. J Clin Oncol 38:1346–1366. https://doi.org/10.1200/jco.19.02309
doi: 10.1200/jco.19.02309
pubmed: 31928404
Hammond MEH, Hayes DF, Dowsett M et al (2010) American society of clinical oncology/college of american pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer. J Clin Oncol 28:2784–2795. https://doi.org/10.1200/jco.2009.25.6529
doi: 10.1200/jco.2009.25.6529
pubmed: 20404251
pmcid: 2881855
Stata statistical software: release 15 (2017) StataCorp LLC, College Station, TX, USA
Lee JM, Ichikawa LE, Wernli KJ et al (2021) Digital mammography and breast tomosynthesis performance in women with a personal history of breast cancer, 2007–2016. Radiology 300:290–300. https://doi.org/10.1148/radiol.2021204581
doi: 10.1148/radiol.2021204581
pubmed: 34003059
Niraula S, Biswanger N, Hu P et al (2020) Incidence, characteristics, and outcomes of interval breast cancers compared with screening-detected breast cancers. JAMA Netw Open 3:e2018179. https://doi.org/10.1001/jamanetworkopen.2020.18179
doi: 10.1001/jamanetworkopen.2020.18179
pubmed: 32975573
pmcid: 7519419
Gluskin J, Saccarelli CR, Avendano D et al (2020) Contrast-enhanced mammography for screening women after breast conserving surgery. Cancers 12:3495. https://doi.org/10.3390/cancers12123495
doi: 10.3390/cancers12123495
pubmed: 33255412
pmcid: 7760311
Sung JS, Lebron L, Keating D et al (2019) Performance of dual-energy contrast-enhanced digital mammography for screening women at increased risk of breast cancer. Radiology 293:182660. https://doi.org/10.1148/radiol.2019182660
doi: 10.1148/radiol.2019182660
Berg WA, Zhang Z, Lehrer D et al (2012) Detection of breast cancer with addition of annual screening ultrasound or a single screening MRI to mammography in women with elevated breast cancer risk. JAMA 307:1394–1404. https://doi.org/10.1001/jama.2012.388
doi: 10.1001/jama.2012.388
pubmed: 22474203
pmcid: 3891886
Veenhuizen SGA, de Lange SV, Bakker MF et al (2021) Supplemental breast MRI for women with extremely dense breasts: results of the second screening round of the DENSE trial. Radiology 299:203633. https://doi.org/10.1148/radiol.2021203633
doi: 10.1148/radiol.2021203633
Lu WL, Jansen L, Post WJ et al (2008) Impact on survival of early detection of isolated breast recurrences after the primary treatment for breast cancer: a meta-analysis. Breast Cancer Res Tr 114:403. https://doi.org/10.1007/s10549-008-0023-4
doi: 10.1007/s10549-008-0023-4
Wernli KJ, Ichikawa L, Kerlikowske K et al (2019) Surveillance breast mri and mammography: comparison in women with a personal history of breast cancer. Radiology 292:311–318. https://doi.org/10.1148/radiol.2019182475
doi: 10.1148/radiol.2019182475
pubmed: 31161975
Slanetz PJ (2021) MRI screening of women with a personal history of breast cancer. Radiology 300:324–325. https://doi.org/10.1148/radiol.2021211080
doi: 10.1148/radiol.2021211080
pubmed: 34100686
Thompson CM, Mallawaarachchi I, Dwivedi DK et al (2019) The Association of background parenchymal enhancement at breast MRI with breast cancer: a systematic review and meta-analysis. Radiology 292:552–561. https://doi.org/10.1148/radiol.2019182441
doi: 10.1148/radiol.2019182441
pubmed: 31237494
Arasu VA, Miglioretti DL, Sprague BL et al (2019) Population-based assessment of the association between magnetic resonance imaging background parenchymal enhancement and future primary breast cancer risk. J Clin Oncol 37:954–963. https://doi.org/10.1200/jco.18.00378
doi: 10.1200/jco.18.00378
pubmed: 30625040
pmcid: 6494266
Cheun J-H, Kim H-K, Moon H-G et al (2023) locoregional recurrence patterns in patients with different molecular subtypes of breast cancer. JAMA Surg 158:841–852. https://doi.org/10.1001/jamasurg.2023.2150
doi: 10.1001/jamasurg.2023.2150
pubmed: 37342035
pmcid: 10285677
J D, Donnelly P, Elbeltagi N, et al (2023) Mammographic surveillance in early breast cancer patients aged 50 years or over: results of the mammo-50 non-inferiority trial of annual versus less frequent mammography. In: San Antonio Breast cancer Symposium
Berg WA, Bandos AI, Sava MG (2023) Analytic hierarchy process analysis of patient preferences for contrast-enhanced mammography versus mri as supplemental screening options for breast cancer. J Am Coll Radiol 20:758–768. https://doi.org/10.1016/j.jacr.2023.05.014
doi: 10.1016/j.jacr.2023.05.014
pubmed: 37394083
Houben IPL, de Voorde PV, Jeukens CRLPN et al (2017) Contrast-enhanced spectral mammography as work-up tool in patients recalled from breast cancer screening has low risks and might hold clinical benefits. Eur J Radiol 94:31–37. https://doi.org/10.1016/j.ejrad.2017.07.004
doi: 10.1016/j.ejrad.2017.07.004
pubmed: 28941757